Skip to content
DataLookout
Menu

NCT07885306

Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment increased: 9 → 10 participants
  2. Minor Study sites: 2 to 4
    • Secondary endpoints revised (5)
  3. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Dose-Limiting Toxicities
Timeframe: From the first dose through Day 28

Secondary (5)

Treatment-Related Adverse Event
Objective Response Rate
Disease Control Rate
Progression-Free Survival
Overall Survival

Arms and interventions

Ivonescimab Plus Pemetrexed and Platinum-Based ChemotherapyExperimental

A single experimental arm consisting of sequential ivonescimab dose-escalation cohorts using a conventional 3+3 design.

Drugs: Ivonescimab Combined With Chemotherapy

Sites

4 sites in 1 country